1. Home
  2. NVVE vs BIVI Comparison

NVVE vs BIVI Comparison

Compare NVVE & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuvve Holding Corp.

NVVE

Nuvve Holding Corp.

HOLD

Current Price

$3.46

Market Cap

8.2M

Sector

Energy

ML Signal

HOLD

Logo BioVie Inc.

BIVI

BioVie Inc.

HOLD

Current Price

$1.35

Market Cap

8.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NVVE
BIVI
Founded
1996
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Oil Refining/Marketing
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.2M
8.7M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
NVVE
BIVI
Price
$3.46
$1.35
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
240.8K
120.4K
Earning Date
11-13-2025
02-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$4,630,156.00
N/A
Revenue This Year
$892.33
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.98
$1.10
52 Week High
$200.80
$25.76

Technical Indicators

Market Signals
Indicator
NVVE
BIVI
Relative Strength Index (RSI) 67.51 46.83
Support Level $1.98 $1.26
Resistance Level $4.14 $1.26
Average True Range (ATR) 0.52 0.11
MACD -0.10 0.01
Stochastic Oscillator 63.22 58.55

Price Performance

Historical Comparison
NVVE
BIVI

About NVVE Nuvve Holding Corp.

Nuvve Holding Corp is accelerating the electrification of transportation through its proprietary vehicle-to-grid (V2G) technology. It helps to support the integration of renewable energy sources, including solar and wind. Its Grid Integrated Vehicle (GIV) platform is refueling the next generation of electric vehicle fleets through bidirectional charging solutions. It has a geographic presence in the United States, the United Kingdom, and Denmark, of which it generates the majority of its revenue in the United States.

About BIVI BioVie Inc.

BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.

Share on Social Networks: